CVRx Inc CVRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CVRX is a good fit for your portfolio.
News
-
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
-
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
-
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
-
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
Trading Information
- Previous Close Price
- $17.99
- Day Range
- $17.86–18.60
- 52-Week Range
- $8.38–33.14
- Bid/Ask
- $17.85 / $18.58
- Market Cap
- $381.09 Mil
- Volume/Avg
- 322,718 / 144,013
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 200
- Website
- https://www.cvrx.com
Comparables
Valuation
Metric
|
CVRX
|
NARI
|
ANIK
|
---|---|---|---|
Price/Earnings (Normalized) | — | 515.48 | — |
Price/Book Value | 5.01 | 5.96 | 1.75 |
Price/Sales | 9.62 | 5.52 | 2.23 |
Price/Cash Flow | — | 81.82 | 36.02 |
Price/Earnings
CVRX
NARI
ANIK
Financial Strength
Metric
|
CVRX
|
NARI
|
ANIK
|
---|---|---|---|
Quick Ratio | 12.48 | 2.43 | 3.50 |
Current Ratio | 14.25 | 3.09 | 5.26 |
Interest Coverage | −21.82 | −56.99 | — |
Quick Ratio
CVRX
NARI
ANIK
Profitability
Metric
|
CVRX
|
NARI
|
ANIK
|
---|---|---|---|
Return on Assets (Normalized) | −30.99% | 5.07% | −1.35% |
Return on Equity (Normalized) | −39.58% | 6.37% | −1.65% |
Return on Invested Capital (Normalized) | −32.19% | 3.35% | −2.24% |
Return on Assets
CVRX
NARI
ANIK
Medical Devices Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ABT
| Abbott Laboratories | Bwwxcsqk | Bygwzc | $197.2 Bil | |
SYK
| Stryker Corp | Mnccdqwv | Cqt | $136.2 Bil | |
MDT
| Medtronic PLC | Rtfsbtts | Vcmmp | $115.7 Bil | |
BSX
| Boston Scientific Corp | Qxykrvkv | Nckrx | $100.7 Bil | |
EW
| Edwards Lifesciences Corp | Xklgvqgst | Tnxvy | $57.5 Bil | |
DXCM
| DexCom Inc | Whhqzysn | Mvf | $53.5 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Dfjmlpmmc | Ymgb | $27.1 Bil | |
ALGN
| Align Technology Inc | Pnfcvymc | Rbsyc | $24.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Fctzlvldt | Pvybyt | $18.2 Bil | |
PODD
| Insulet Corp | Hdfgbtxk | Fdhpddl | $12.0 Bil |